Eli Lilly

Oncolytics Biotech® Appoints Patricia S. Andrews to its Board of Directors

Retrieved on: 
Tuesday, January 9, 2024
Renal cell carcinoma, SAN, University, Novartis, Pelareorep, Pfizer, Ruxolitinib, Eli Lilly, MBA, AB, TSX, Breast, Colorectal cancer, Senior, Poverty, Audit committee, Brown University, ONC, Management

SAN DIEGO and CALGARY, AB, Jan. 9, 2024 /PRNewswire/ --  Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, today announced the appointment of Patricia S. Andrews to its Board of Directors (the "Board").

Key Points: 
  • SAN DIEGO and CALGARY, AB, Jan. 9, 2024 /PRNewswire/ --  Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, today announced the appointment of Patricia S. Andrews to its Board of Directors (the "Board").
  • "I am pleased to welcome Pat Andrews to our Board of Directors," said Dr. Matt Coffey, President and Chief Executive Officer of Oncolytics.
  • "Pat's extensive board and executive leadership experience navigating first registrational trials in oncology and completing transformational business development agreements with global pharmaceutical companies makes her a natural fit for Oncolytics.
  • "I am honored to join the Oncolytics board at this exciting time for the organization as it advances pelareorep toward registrational studies," said Ms. Andrews.

Oncolytics Biotech® Appoints Patricia S. Andrews to its Board of Directors

Retrieved on: 
Tuesday, January 9, 2024
Renal cell carcinoma, SAN, University, Novartis, Pelareorep, Pfizer, Ruxolitinib, Eli Lilly, MBA, AB, TSX, Breast, Colorectal cancer, Senior, Poverty, Audit committee, Brown University, ONC, Management

SAN DIEGO and CALGARY, AB, Jan. 9, 2024 /PRNewswire/ --  Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, today announced the appointment of Patricia S. Andrews to its Board of Directors (the "Board").

Key Points: 
  • SAN DIEGO and CALGARY, AB, Jan. 9, 2024 /PRNewswire/ --  Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, today announced the appointment of Patricia S. Andrews to its Board of Directors (the "Board").
  • "I am pleased to welcome Pat Andrews to our Board of Directors," said Dr. Matt Coffey, President and Chief Executive Officer of Oncolytics.
  • "Pat's extensive board and executive leadership experience navigating first registrational trials in oncology and completing transformational business development agreements with global pharmaceutical companies makes her a natural fit for Oncolytics.
  • "I am honored to join the Oncolytics board at this exciting time for the organization as it advances pelareorep toward registrational studies," said Ms. Andrews.

Enhancing Leadership in Gynecology, Asieris Pharmaceuticals Appoints Sophia Cao to Lead the Newly-Established Women's Health Business Unit, Accelerating Strategic Expansion

Retrieved on: 
Tuesday, January 9, 2024
Action plan, E pluribus unum, Woman, Bladder cancer, Marketing, Health, Elimination, Society, Cancer, Cervical cancer, Infection, World Health Organization, Diagnosis, NMIBC, Comparison, Cervical weakness, Multimedia, Death, ASCO, Breast cancer, Eli Lilly, Tislelizumab, Prevalence, MIBC, Neoadjuvant therapy, HPV, Human papillomavirus infection, LSIL, New Drug Application, NMPA, National Health Commission, Central China, Kidney cancer, Women's health, National Cancer Center, PD-1, WHO, Mortality, HSIL, Conditional sentence, Internet, Weak topology, Patient, Senior, State Council, NDA, Incidence, Head, National Medical Products Administration, Miscarriage

This strategic move is designed to enhance the company's focus on genitourinary diseases and strengthen its position in women's health.

Key Points: 
  • This strategic move is designed to enhance the company's focus on genitourinary diseases and strengthen its position in women's health.
  • Asieris Pharmaceuticals will leverage both in-house discoveries and external partnerships to enrich its gynecological portfolio, thereby reinforcing its leadership in women's health.
  • In November 2020, the World Health Organization (WHO) released a Global Strategy to Accelerate the Elimination of Cervical Cancer.
  • To further deliver its strategic vision and commitment in the realm of women's health, Asieris Pharmaceuticals has announced the establishment of the Women's Health Business Unit.

Ginkgo Bioworks Announces Inaugural Members of New Biopharma Advisory Board

Retrieved on: 
Monday, January 8, 2024
Commercial, Boehringer Ingelheim, DNA, Cancer, Investment, Novartis, SVP, Fermentation, Beam, Atlas, Kite Pharma, RNA interference, Sensible, Drug discovery, AbbVie, Invention, Biotechnology Innovation Organization, Eli Lilly, MBA, HIV, Merck, Therapy, Creativity, Epidemiology, RNA, GSK plc, DARPA, Process, WARF, Johnson & Johnson, Movement, Ginkgo Bioworks, Novo Nordisk, AI, Atlas Venture, AAV, Patient, Medicine, Synthetic biology, Senior, M28, Acquisition, BIO, MD, Doctor of Philosophy, Eli Lilly and Company, Hematology, Growth, Avantor, Infection, Pharmaceutical industry

BOSTON, Jan. 8, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced the formation of its new Biopharma Advisory Board.

Key Points: 
  • BOSTON, Jan. 8, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced the formation of its new Biopharma Advisory Board.
  • "The discovery and development of new medicines is critically important and incredibly challenging," said Jason Kelly, co-founder and CEO of Ginkgo Bioworks.
  • "I'm excited to welcome this incredible deep bench of wisdom and creativity to the Ginkgo family," said Jennifer Wipf, SVP & Head of Commercial at Ginkgo Bioworks.
  • Now more than ever, the speed of drug discovery and development is important," said Norbert Bischofberger, Ginkgo Biopharma Advisory Board member.

StartUp Health Launches Global Alzheimer's Moonshot with Support from the Alzheimer's Drug Discovery Foundation (ADDF) and Gates Ventures

Retrieved on: 
Monday, January 8, 2024
Fillit, Moon, Entrepreneurship, Conference, Partnership, Learning, Gates Ventures, Research, Eli Lilly, Human, Fellow, MD, SAN, Dual-energy X-ray absorptiometry, Medicine, Biomarker, Growth, Patient, Diagnosis, History, Dementia, Therapy, Pharmaceutical industry

SAN FRANCISCO, Jan. 8, 2024 /PRNewswire-PRWeb/ -- During the 42nd Annual J.P. Morgan Healthcare Conference week, StartUp Health, in partnership with the Alzheimer's Drug Discovery Foundation's (ADDF) Diagnostics Accelerator (DxA), and Gates Ventures, the private office of Bill Gates, announced the launch of the Alzheimer's Moonshot. This initiative aims to break down silos and foster meaningful collaboration between mission-aligned founders, funders, and partners, accelerating progress in preventing, managing, and curing Alzheimer's and related dementias through the support of entrepreneurial innovation. The Alzheimer's Moonshot is an invitation to Health Transformers, Alzheimer's funders, foundations, advocates, and innovators, as well as leading startups and research teams, to unite in pioneering comprehensive, collaborative approaches to Alzheimer's disease.

Key Points: 
  • SAN FRANCISCO, Jan. 8, 2024 /PRNewswire-PRWeb/ -- During the 42nd Annual J.P. Morgan Healthcare Conference week, StartUp Health , in partnership with the Alzheimer's Drug Discovery Foundation 's (ADDF) Diagnostics Accelerator (DxA), and Gates Ventures, the private office of Bill Gates, announced the launch of the Alzheimer's Moonshot.
  • "The ADDF welcomes the opportunity to partner with StartUp Health to launch the Alzheimer's Moonshot," notes Howard Fillit, MD, Co-Founder and Chief Science Officer at the ADDF.
  • Are you an academic founder, founder, startup or research team focused on Alzheimer's innovation who would like to join the Alzheimer's Moonshot?
  • To explore how your organization can become part of the Alzheimer's Moonshot (or one of our 14 global health moonshots) please reach out to us at [email protected] .

Immunome Appoints Phil Roberts as Chief Technical Officer

Retrieved on: 
Thursday, January 4, 2024
Biotechnology, Pharmaceutical, Health, Oncology, Research, Eli Lilly, Spacecraft, Roche, CMC, Rensselaer Polytechnic Institute, Mirati Therapeutics, Chemical engineering, Doctor of Philosophy, Louisiana State University, Clay, SVP

Immunome , Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the appointment of Phil Roberts as Chief Technical Officer.

Key Points: 
  • Immunome , Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the appointment of Phil Roberts as Chief Technical Officer.
  • Mr. Roberts has over three decades of experience in product development, global manufacturing, and commercialization of novel pharmaceutical products.
  • “Immunome is delighted to add Phil to our management team as we advance our portfolio of immunotherapies, radioligand therapies, and ADCs towards clinical development,” stated Clay Siegall, PhD, President and Chief Executive Officer of Immunome.
  • Prior to that, Mr. Roberts served as SVP, Technical Operations at Mirati Therapeutics, where he was responsible for pharmaceutical product development, manufacturing, and supply chain operations.

ReAlta Life Sciences Strengthens Board of Directors with Appointment of Three Accomplished Biotechnology Executives

Retrieved on: 
Wednesday, January 3, 2024
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Clinical Trials, Kite Pharma, Engineering management, Tufts University, Marketing, Lilly, Migraine, Johnson & Johnson, Amgen, Sale, AstraZeneca, Daiichi Sankyo, Eli Lilly, Jan Vansina, Business administration, Engineering, WebMD, MBA, Chemical engineering, Doctor of Philosophy, Roivant Sciences, Therapy, Eli Lilly and Company, Consumer service, University, Washington State University, Worcester Polytechnic Institute, Iowa State University, SVP, Corporation, Pharmaceutical industry

ReAlta Life Sciences, Inc. (“ReAlta” or the “Company”), a mid-stage clinical biotech company dedicated to saving lives by rebalancing the inflammatory response to address life-threatening diseases, today announced the appointment of three seasoned biotechnology executives, Christi Shaw, Mert Aktar, and David Marek, to its Board of Directors, effective immediately.

Key Points: 
  • ReAlta Life Sciences, Inc. (“ReAlta” or the “Company”), a mid-stage clinical biotech company dedicated to saving lives by rebalancing the inflammatory response to address life-threatening diseases, today announced the appointment of three seasoned biotechnology executives, Christi Shaw, Mert Aktar, and David Marek, to its Board of Directors, effective immediately.
  • “We are delighted to welcome Christi Shaw, Mert Aktar and David Marek, and the tremendous expertise and wise counsel they represent, to our Board of Directors,” said Buzz Heidt, Chairman of ReAlta's Board of Directors.
  • Prior to Kite, Ms. Shaw served as an executive officer of Eli Lilly and Company (Lilly), a global healthcare company, and president of Lilly Bio-Medicines.
  • Mr. Aktar is an accomplished life sciences industry executive with over twenty years of multinational experience bridging science and business in pharmaceuticals and biotechnology.

Psychiatry and Neuroscience Expert Dr. Joel Raskin Joins ArrivoBio as Chief Medical Advisor

Retrieved on: 
Wednesday, January 3, 2024
Mental Health, Health, Other Science, Research, Science, Pharmaceutical, Biotechnology, Mental health service, Disease, Lilly, Dementia, CMA, Migraine, Multimedia, Mental health, Addiction, Pharmacy, Drug discovery, Eli Lilly, CMO, Pain, Depression, University, FRCP, Alzheimer's disease, Schizophrenia, University of Toronto, Anxiety, Therapy, DSM-IV codes, Pharmaceutical industry

Arrivo BioVentures proudly announces the appointment of Dr. Joel Raskin as its Chief Medical Advisor (CMA).

Key Points: 
  • Arrivo BioVentures proudly announces the appointment of Dr. Joel Raskin as its Chief Medical Advisor (CMA).
  • View the full release here: https://www.businesswire.com/news/home/20240103994981/en/
    Dr. Joel Raskin joins ArrivoBio as Chief Medical Advisor.
  • (Photo: Business Wire)
    “We are honored to welcome Dr. Joel Raskin to our team as we continue to advance our novel therapies SP-624 and RABI-767,” said Steve Butts, CEO of Arrivo.
  • Over the course of his career, Dr. Raskin has published nearly 100 scientific articles.

Star Therapeutics Appoints Scott Robertson, MBA, as Chief Business Officer and Chief Financial Officer

Retrieved on: 
Wednesday, January 3, 2024
Biotechnology, Pharmaceutical, Health, Biology, Multimedia, Business, Star, Acquisition, Eli Lilly, Business administration, Merrill (company), MBA, Doctor of Philosophy, Therapy, Pioneer Hi Bred International, University, Growth, Patient, Triple accreditation, Thomas Weisel Partners

Star Therapeutics , a biotechnology company interrogating novel biology to develop life-changing therapies, today announced the appointment of Scott Robertson, MBA, as Chief Business Officer and Chief Financial Officer.

Key Points: 
  • Star Therapeutics , a biotechnology company interrogating novel biology to develop life-changing therapies, today announced the appointment of Scott Robertson, MBA, as Chief Business Officer and Chief Financial Officer.
  • Mr. Robertson brings more than twenty years of experience with corporate strategy, business operations, capital raising and M&A.
  • View the full release here: https://www.businesswire.com/news/home/20240103822562/en/
    Star CFO-CBO Scott Robertson (Photo: Business Wire)
    “We are excited to welcome Scott to the Star leadership team during this time of significant growth,” said Adam Rosenthal, PhD, Chief Executive Officer and Founder of Star Therapeutics.
  • “I’m very excited to join the Star Therapeutics team at a time of great momentum with its proven approach for translating novel biology into first-in-class antibody therapies.

SpliceBio Appoints Leading Ophthalmology Expert Aniz Girach as Chief Medical Officer

Retrieved on: 
Wednesday, January 3, 2024
Conference, Wills Eye Hospital, Biotechnology, Paratriathlon, Medicine, Nightstar, Acquisition, Eli Lilly, Alcon, Retina, ProQR, Drug, MD, Ocriplasmin, Merck & Co., Stargardt disease, Abstract, Protein splicing, Laboratory, Stargardt, Merck, Gene, Genetic, Growth, Biogen, Pharmaceutical industry

BARCELONA, Spain, Jan. 3, 2024 /PRNewswire/ -- SpliceBio, a genetic medicines company harnessing Protein Splicing to develop the next generation of gene therapies, is pleased to announce the appointment of Aniz Girach, MD as Chief Medical Officer.

Key Points: 
  • BARCELONA, Spain, Jan. 3, 2024 /PRNewswire/ -- SpliceBio, a genetic medicines company harnessing Protein Splicing to develop the next generation of gene therapies, is pleased to announce the appointment of Aniz Girach, MD as Chief Medical Officer.
  • Dr Girach was Global Head of Ophthalmology at Merck & Co and Vice President, Clinical Development at Alcon Laboratories.
  • Prior to joining SpliceBio, he led the development of genetic therapies for inherited retinal diseases at ProQR Therapeutics NV as its Chief Medical Officer.
  • Aniz Girach, MD., Chief Medical Officer of SpliceBio, commented: "Inherited retinal diseases are a heterogenous group of rare diseases that can lead to severe visual disability and blindness, affecting approximately 5.5 million people worldwide.